Since the publication of this paper, the authors have noticed an error on page 3 of their article. The correct sentence is shown below: 'In the phase III study of nilotinib versus imatinib as first-line treatment for patients with CP CML, patients receiving imatinib were more likely to experience all-grade peripheral edema, eyelid edema and periorbital edema (14, 13 and 12%, respectively) than patients receiving nilotinib 300 mg twice daily (5, 1 and o1%, respectively) or nilotinib 400 mg twice daily (5, 2 and 1%, respectively).'
The authors apologize for any inconvenience caused. Correction to: Leukemia (2010 Leukemia ( ) 11, 1927 Leukemia ( -1933 doi:10.1038 / leu.2010 Since the publication of the above paper, the authors have noticed an error in Supplementary Tables 1 and 3. The authors would like to apologise for any inconvenience this may have caused.
The corrected supplementary tables can be accessed via the online version of this corrigendum. Leukemia (2011 ) 25, 385 & 2011 www.nature.com/leu
